Invesco Exchange-Traded Self-Indexed Fund Trust has released its latest financial report, detailing significant figures that highlight the fund's current standing. The NPORT-P filing, submitted on October 30, 2026, reveals that the fund holds total assets of approximately $828.8 million and net assets of about $809.2 million as of August 31, 2026. This update is crucial as it underscores the fund's financial health and compliance with regulatory standards.
Established as an investment entity, Invesco Exchange-Traded Self-Indexed Fund Trust operates under the SEC Act of 1940. The fund's recent filing, accession number 0001657201-26-000786, is part of a series of disclosures made on the same day, indicating a proactive approach to transparency in its operations. The filing includes details about the fund's assets and liabilities, showcasing a total liability of approximately $19.7 million.
The NPORT-P filing provides insights into the fund's investment strategies and performance metrics. The report shows that the fund's assets are diversified across various corporate bonds, with notable investments in companies such as Cushman & Wakefield U.S. Borrower, LLC, IQVIA Inc., and RingCentral, Inc. This diversification may help mitigate risks associated with market fluctuations.
The impact of this filing extends beyond just the fund itself. Investors and stakeholders in the investment management sector will closely analyze these figures, as they reflect the overall health of similar funds in the industry. The reported total assets and net assets may influence investor confidence, potentially affecting market dynamics for exchange-traded funds (ETFs) and other investment vehicles.
Looking ahead, the filing does not specify what actions will follow this report. However, the consistent updates and transparency from Invesco suggest a commitment to maintaining investor trust and adhering to regulatory requirements. As the investment landscape evolves, stakeholders will be keen to monitor further disclosures and performance metrics from the fund.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






